Unnecessary Psychotropic Medication Use Without Reassessment
Summary
The facility failed to ensure one resident remained free from chemical restraint use when Buspirone was initiated and later increased without documented evidence that underlying medical conditions were ruled out or that nonpharmacological interventions were attempted first. The resident had diagnoses including non-Alzheimer’s dementia, hyperlipidemia, and traumatic brain injury, and the quarterly MDS documented severely impaired cognition with antianxiety medication use 7 days a week. The care plan identified Buspirone for anxiety disorder with interventions to monitor behavior and medication effectiveness. Psychiatry documentation before the medication change noted the resident had no complaints and denied anxiety or depression symptoms, and the last psychiatry follow-up was on 05/13/2025. On 08/09/2025, a physician evaluated the resident for reported agitation and ordered Buspirone 5 mg daily, but the record did not show nonpharmacological interventions or evaluation for underlying causes before starting the medication. Later notes documented anxiety, agitation, pacing, verbal outbursts, restlessness, and noncompliance with care, but there was no documented evidence that psychiatry was reconsulted or that underlying medical conditions were ruled out when behaviors increased. The resident was transferred to the hospital on 10/03/2025 after increased agitation and refusal of evaluation, and Buspirone was increased to 5 mg twice daily to help the resident comply with transfer for further evaluation. The resident was then diagnosed with an acute urinary tract infection and treated with ceftriaxone, but there was no documented evidence that the need for the increased Buspirone dose was reassessed after the infection was treated and the resident was no longer displaying the behaviors that had prompted the medication change. Later behavior notes described the resident as calm and quiet, and the record also showed the resident expressed concern about needing certain medications and feeling fine without them, yet the continued necessity of Buspirone was not documented as being evaluated.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.